How to buy Avenue Therapeutics stock

Avenue Therapeutics, Inc is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Avenue Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Avenue Therapeutics share price

Use our graph to track the performance of ATXI stocks over time.

Avenue Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$2.85 - $12.34
50-day moving average	$5.77
200-day moving average	$5.09
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.96

Buy Avenue Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Avenue Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Avenue Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avenue Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-53.59%
Return on equity TTM	-112.48%
Profit margin	0%
Book value	$0.14
Market capitalisation	$85.8 million

TTM: trailing 12 months

Shorting Avenue Therapeutics shares

There are currently 617,452 Avenue Therapeutics shares held short by investors – that's known as Avenue Therapeutics's "short interest". This figure is 37.6% up from 448,687 last month.

There are a few different ways that this level of interest in shorting Avenue Therapeutics shares can be evaluated.

Avenue Therapeutics's "short interest ratio" (SIR)

Avenue Therapeutics's "short interest ratio" (SIR) is the quantity of Avenue Therapeutics shares currently shorted divided by the average quantity of Avenue Therapeutics shares traded daily (recently around 518867.22689076). Avenue Therapeutics's SIR currently stands at 1.19. In other words for every 100,000 Avenue Therapeutics shares traded daily on the market, roughly 1190 shares are currently held short.

However Avenue Therapeutics's short interest can also be evaluated against the total number of Avenue Therapeutics shares, or, against the total number of tradable Avenue Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avenue Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Avenue Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0931% of the tradable shares (for every 100,000 tradable Avenue Therapeutics shares, roughly 93 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avenue Therapeutics.

Find out more about how you can short Avenue Therapeutics stock.

Avenue Therapeutics share dividends

We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.

Avenue Therapeutics share price volatility

Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $2.85 up to $12.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is 0.7457. This would suggest that Avenue Therapeutics's shares are less volatile than average (for this exchange).

Avenue Therapeutics overview

Avenue Therapeutics, Inc. , a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York. .

Frequently asked questions

• What percentage of Avenue Therapeutics is owned by insiders or institutions?

  Currently 60.295% of Avenue Therapeutics shares are held by insiders and 12.317% by institutions.

• How many people work for Avenue Therapeutics?

  Latest data suggests 4 work at Avenue Therapeutics.

• When does the fiscal year end for Avenue Therapeutics?

  Avenue Therapeutics's fiscal year ends in December.

• Where is Avenue Therapeutics based?

  Avenue Therapeutics's address is: 1140 Avenue of the America, New York, NY, United States, 10036

• What is Avenue Therapeutics's ISIN number?

  Avenue Therapeutics's international securities identification number is: US05360L2051

• What is Avenue Therapeutics's CUSIP number?

  Avenue Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05360L106